Rishabh Jain, Medical Oncologist at AIIMS, shared on X:
“Can CDK4/6 inhibition replace chemotherapy even in visceral crisis?
DARVIN, a multicenter phase II trial, evaluated dalpiciclib + endocrine therapy in 53 women with HR+/HER2− advanced breast cancer and visceral crisis.
- 6-month survival: 92.5%
- ORR: 26.4%
- DCR: 79.2%
- Median PFS: 11.2 months
- Median OS: Not reached.
In an IPTW-adjusted external comparison. Dalpiciclib + ET vs chemotherapy:
- Median PFS: 11.2 vs 4.6 months
- HR 0.30, P<0.0001
- Grade ≥3 neutropenia: 77.4%
- Single-arm, nonrandomized study
- Nearly half had effusion-based visceral crisis
- External-control comparison remains hypothesis-generating
Verdict: Promising, not practice-changing yet. This strengthens the case that selected patients with HR+/HER2- visceral crisis may not automatically require chemotherapy. Would this change your first-line approach?”
You can also find this interesting:
The CDK4/6 Inhibitor Story Is Entering Its Next Chapter in Breast Cancer
